JP2017534569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534569A5 JP2017534569A5 JP2017502270A JP2017502270A JP2017534569A5 JP 2017534569 A5 JP2017534569 A5 JP 2017534569A5 JP 2017502270 A JP2017502270 A JP 2017502270A JP 2017502270 A JP2017502270 A JP 2017502270A JP 2017534569 A5 JP2017534569 A5 JP 2017534569A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- hexadeca
- trifluoromethyl
- pentaazatetracyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 62
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 61
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- -1 3- (trifluoromethyl) phenyl Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 238000001311 chemical methods and process Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024192P | 2014-07-14 | 2014-07-14 | |
| US62/024,192 | 2014-07-14 | ||
| PCT/US2015/040076 WO2016010869A2 (en) | 2014-07-14 | 2015-07-11 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534569A JP2017534569A (ja) | 2017-11-24 |
| JP2017534569A5 true JP2017534569A5 (enExample) | 2018-07-26 |
| JP6380777B2 JP6380777B2 (ja) | 2018-08-29 |
Family
ID=55079153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502270A Active JP6380777B2 (ja) | 2014-07-14 | 2015-07-11 | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10112945B2 (enExample) |
| EP (1) | EP3169687B1 (enExample) |
| JP (1) | JP6380777B2 (enExample) |
| KR (1) | KR102426138B1 (enExample) |
| CN (1) | CN105722840B (enExample) |
| AU (1) | AU2015290007B2 (enExample) |
| CA (1) | CA2954999C (enExample) |
| ES (1) | ES2714100T3 (enExample) |
| WO (1) | WO2016010869A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| US10307412B2 (en) | 2014-12-09 | 2019-06-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative against non-small cell lung cancer |
| US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| CN108601773B (zh) * | 2015-07-11 | 2025-12-19 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的稠合喹啉化合物 |
| CN107296811B (zh) | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
| CN107037153B (zh) * | 2017-04-21 | 2019-05-14 | 常州佳德医药科技有限公司 | 高效液相色谱法检测al58805原料药或药物制剂中基因毒性杂质的方法 |
| AU2019227391B2 (en) | 2018-03-02 | 2024-06-13 | Advenchen Laboratories Nanjing Ltd. | Crystal of compound as c-Met kinase inhibitor and preparation method therefor and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AU2008218806B2 (en) * | 2007-02-20 | 2011-12-01 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mTOR inhibitors |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| US20110212053A1 (en) * | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| IT1393351B1 (it) | 2009-03-16 | 2012-04-20 | Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
| CN102344438B (zh) | 2010-08-01 | 2014-02-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶及其制备方法 |
| SG188302A1 (en) * | 2010-09-16 | 2013-04-30 | Hutchison Medipharma Ltd | Fused heteroaryls and their uses |
| HK1217328A1 (zh) | 2013-01-18 | 2017-01-06 | Advenchen Pharmaceuticals Llc | 製備抗腫瘤劑 6-(7-((1-氨基環丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其結晶 |
| CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
-
2015
- 2015-07-11 KR KR1020177003884A patent/KR102426138B1/ko active Active
- 2015-07-11 ES ES15821295T patent/ES2714100T3/es active Active
- 2015-07-11 CN CN201580000818.6A patent/CN105722840B/zh active Active
- 2015-07-11 JP JP2017502270A patent/JP6380777B2/ja active Active
- 2015-07-11 US US15/325,593 patent/US10112945B2/en active Active
- 2015-07-11 WO PCT/US2015/040076 patent/WO2016010869A2/en not_active Ceased
- 2015-07-11 EP EP15821295.1A patent/EP3169687B1/en active Active
- 2015-07-11 CA CA2954999A patent/CA2954999C/en active Active
- 2015-07-11 AU AU2015290007A patent/AU2015290007B2/en not_active Ceased